Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filings
MORE TOOLS
WatchlistGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View KMTS insider activity ↗

KMTSKESTRA MEDICAL TECHNOLOGIES, LTD.

THE LATEST REPORTED YEAR

The company reported a loss.

$131.61M net loss for the year ended April 30, 2026. These are reported results, not a forecast or a stock recommendation.

Revenue$95.13MYear ended April 30, 2026
Profit or loss-$131.61MYear ended April 30, 2026
Cash from the business-$81.7MYear ended April 30, 2026
Total assets$347.36MAs of July 31, 2026
Total liabilities$125MAs of July 31, 2026
Cash & equivalents$68.56MAs of July 31, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$27.81M
2024-04
$59.82M
2025-04
$95.13M
2026-04

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
May 1, 2025 – April 30, 2026$95,126,000July 14, 202610-K ↗
May 1, 2024 – April 30, 2025$59,815,000July 14, 202610-K ↗
May 1, 2023 – April 30, 2024$27,814,000July 17, 202510-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 12, 2026

Response SHA-256: 349255c9a0b63038a49963b03c273268a4ab92a4aa83703220500dec893270fb

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.